Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer.
Yun Hee Kang; Na Young Ji; Seung Ro Han; Chung Il Lee; Jae Wha Kim; Young Il Yeom; Young Ho Kim; Ho Kyung Chun; Jong Wan Kim; Jin Woong Chung; et al. (Profiled Author: Na Ji)
Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Cellular signalling 2012;24(10):1940-9.
In our previous study, we reported that endothelial cell specific molecule-1 (ESM-1) was increased in tissue and serum from colorectal cancer patients and suggested that ESM-1 can be used as a potential serum marker for early detection of colorectal cancer. The aim of this study was to evaluate the role of ESM-1 as an intracellular molecule in colorectal cancer. ESM-1 expression was knocked down by small interfering RNA (siRNA) in colorectal cancer cells. Expression of ESM-1 siRNA decreased cell survival through the Akt-dependent inhibition of NF-κB/IκB pathway and an interconnected reduction in phospho-Akt, -p38, -ERK1, -RSK1, -GSK-3α/β and -HSP27, as determined by a phospho-MAPK array. ESM-1 silencing induced G(1) phase cell cycle arrest by induction of PTEN, resulting in the inhibition of cyclin D1 and inhibited cell migration and invasion of COLO205 cells. Consistently, ESM-1 overexpression in HCT-116 cells enhanced cell proliferation through the Akt-dependent activation of NF-κB pathway. In addition, ESM-1 interacted with NF-κB and activated NF-κB promoter. This study demonstrates that ESM-1 is involved in cell survival, cell cycle progression, migration, invasion and EMT during tumor invasion in colorectal cancer. Based on our results, ESM-1 may be a useful therapeutic target for colorectal cancer.
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Publications
-
1.
2011Yun Hee Kang; Na Young Ji; Chung Il Lee; Hee Gu Lee; Jae Wha Kim; Young Il Yeom; Dae Ghon Kim; Seung Kew Yoon; Jong Wan Kim; Pil Je Park; et al.
Amino acids 2011;40(3):1003-13. -
2.
2005Benjamin W Purow; Raqeeb M Haque; Martha W Noel; Qin Su; Michael J Burdick; Jeongwu Lee; Tilak Sundaresan; Sandra Pastorino; John K Park; Irina Mikolaenko; et al.
Cancer research 2005;65(6):2353-63. -
3.
2007Ben Ho Park; Nancy E Davidson
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
Cancer cell 2007;12(4):297-9.
Related Topics
Appears in this Publication
Related Experts
Author of this Publication
-
Internal ExpertsPublications
-
8









-
123









-
32









-
454









-
298









-
62









